80
Participants
Start Date
March 31, 2012
Primary Completion Date
September 30, 2013
Study Completion Date
March 31, 2018
docetaxel and cisplatin
"* The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~* CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
IMRT
"IMRT is administered with chemotherapy from week 7 to week 13~* GTV（primary tumor）：68-70Gy/35\~38 F，once a day, 5 times per week~* CTV（Clinical target）：56-66Gy/30\~36f，once a day, 5 times per week~* GTV-ln（positive neck region）：66-70Gy/33\~36 F，once a day, 5 times per week~* CTV-ln（negative neck region）：50-54Gy/28\~30F, once a day, 5 times"
Nimotuzumab
Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13\~14 weeks
ACTIVE_NOT_RECRUITING
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing
ACTIVE_NOT_RECRUITING
Guangxi Tumor Hospital, Nanning
ACTIVE_NOT_RECRUITING
GuiZhou Cancer Hospital, Guiyang
RECRUITING
The Second People's Hospital of Sichuan, Chengdu
ACTIVE_NOT_RECRUITING
West China Hospital, Sichuan University, Chengdu
ACTIVE_NOT_RECRUITING
Yunnan Tumor Hospital, The Third Affiliated Hospital of KUNMING Medical University, Kunming
ACTIVE_NOT_RECRUITING
Xijing Hospital, Xi’an
ACTIVE_NOT_RECRUITING
ShanXi Cancer Hospital, Xian
ACTIVE_NOT_RECRUITING
Gansu Province Medical Science Institute, Lanzhou
ACTIVE_NOT_RECRUITING
The Tumor Affiliated Hospital of Ningxia Medical University General Hospita, Yinchuan
ACTIVE_NOT_RECRUITING
Xinjiang tumor hospital, The Third Affiliated Hospital of Xinjiang Medical University, Ürümqi
ACTIVE_NOT_RECRUITING
Neimenggu Tumor Hospital, Baotou
ACTIVE_NOT_RECRUITING
Qinghai Five Hospital, Xining
Collaborators (1)
Biotech Pharmaceutical Co., Ltd.
OTHER
The Second People's Hospital of Sichuan
OTHER